Open AccessAntihypertensive Treatment Prolongs Tissue Plasminogen Activator Door-to-Treatment Time
Author(s) -
Lesli E. Skolarus,
Phillip Scott,
James Burke,
Eric E. Adelman,
Shirley M. Frederiksen,
Allison M. Kade,
J. D. Kalbfleisch,
Andria L. Ford,
William J. Meurer
Publication year - 2012
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.112.662684
Subject(s) - medicine , tissue plasminogen activator , stroke (engine) , t plasminogen activator , thrombolysis , plasminogen activator , surgery , myocardial infarction , mechanical engineering , engineering
Identifying modifiable tissue plasminogen activator treatment delays may improve stroke outcomes. We hypothesized that prethrombolytic antihypertensive treatment (AHT) may prolong door-to-treatment time (DTT).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom